Literature DB >> 24201857

Sildenafil exposure and hemodynamic effect after Fontan surgery.

Robert D Tunks1, Piers C A Barker, Daniel K Benjamin, Michael Cohen-Wolkowiez, Gregory A Fleming, Matthew Laughon, Jennifer S Li, Kevin D Hill.   

Abstract

OBJECTIVE: Determine sildenafil exposure and hemodynamic effect in children after Fontan single-ventricle surgery.
DESIGN: Prospective dose-escalation trial.
SETTING: Single-center pediatric catheterization laboratory. PATIENTS: Nine children post Fontan single-ventricle surgical palliation and undergoing elective cardiac catheterization: median (range) age and weight, 5.2 years (2.5-9.4 yr) and 16.3 kg (9.5-28.1 kg). Five children (55%) were boys, and six of nine (67%) had a systemic right ventricle.
INTERVENTIONS: Catheterization and echocardiography performed before and immediately after single-dose IV sildenafil (0.25, 0.35, or 0.45 mg/kg over 20 min).
MEASUREMENTS AND MAIN RESULTS: Peak sildenafil and desmethyl sildenafil concentration, change in hemodynamic variables measured by cardiac catheterization and echocardiography. Maximum sildenafil concentrations ranged from 124 to 646 ng/mL and were above the in vitro threshold needed for 77% phosphodiesterase type-5 inhibition in eight of nine children and 90% inhibition in seven of seven children with doses more than or equal to 0.35 mg/kg. Sildenafil improved stroke volume (+22%, p = 0.05) and cardiac output (+10%, p = 0.01) with no significant change in heart rate in eight of nine children. Sildenafil also lowered systemic (-16%, p = 0.01) and pulmonary vascular resistance index in all nine children (median baseline pulmonary vascular resistance index 2.4 [range, 1.3-3.7]; decreased to 1.9 [0.8-2.7] Wood Units × m; p = 0.01) with no dose-response effect. Pulmonary arterial pressures decreased (-10%, p = 0.02) and pulmonary blood flow increased (9%, p = 0.02). There was no change in myocardial performance index and no adverse events.
CONCLUSIONS: After Fontan surgery, sildenafil infusion acutely improves cardiopulmonary hemodynamics, increasing cardiac index. For the range of doses studied, exposure was within the acute safety range reported in adult subjects.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24201857      PMCID: PMC3887448          DOI: 10.1097/PCC.0000000000000007

Source DB:  PubMed          Journal:  Pediatr Crit Care Med        ISSN: 1529-7535            Impact factor:   3.624


  31 in total

1.  Noninvasive Doppler-derived myocardial performance index: correlation with simultaneous measurements of cardiac catheterization measurements.

Authors:  C Tei; R A Nishimura; J B Seward; A J Tajik
Journal:  J Am Soc Echocardiogr       Date:  1997-03       Impact factor: 5.251

2.  Functional outcome after the Fontan operation: factors influencing late morbidity.

Authors:  T L Gentles; K Gauvreau; J E Mayer; S B Fishberger; J Burnett; S D Colan; J W Newburger; G Wernovsky
Journal:  J Thorac Cardiovasc Surg       Date:  1997-09       Impact factor: 5.209

3.  Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man.

Authors:  D K Walker; M J Ackland; G C James; G J Muirhead; D J Rance; P Wastall; P A Wright
Journal:  Xenobiotica       Date:  1999-03       Impact factor: 1.908

4.  Effects of sildenafil citrate on human hemodynamics.

Authors:  G Jackson; N Benjamin; N Jackson; M J Allen
Journal:  Am J Cardiol       Date:  1999-03-04       Impact factor: 2.778

5.  Implications of the U.S. Food and Drug Administration warning against the use of sildenafil for the treatment of pediatric pulmonary hypertension.

Authors:  Steven H Abman; John P Kinsella; Erika B Rosenzweig; Usha Krishnan; Thomas Kulik; Mary Mullen; David L Wessel; Robin Steinhorn; Ian Adatia; Brian Hanna; Jeffrey Feinstein; Jeffrey Fineman; Usha Raj; Tilman Humpl
Journal:  Am J Respir Crit Care Med       Date:  2012-12-06       Impact factor: 21.405

6.  Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction.

Authors:  M Boolell; M J Allen; S A Ballard; S Gepi-Attee; G J Muirhead; A M Naylor; I H Osterloh; C Gingell
Journal:  Int J Impot Res       Date:  1996-06       Impact factor: 2.896

7.  Use of sildenafil for safe improvement of erectile function and quality of life in men with New York Heart Association classes II and III congestive heart failure: a prospective, placebo-controlled, double-blind crossover trial.

Authors:  Linda J Webster; Evangelos D Michelakis; Terry Davis; Stephen L Archer
Journal:  Arch Intern Med       Date:  2004-03-08

8.  Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension.

Authors:  Gregory D Lewis; Ravi Shah; Khurram Shahzad; Janice M Camuso; Paul P Pappagianopoulos; Judy Hung; Ahmed Tawakol; Robert E Gerszten; David M Systrom; Kenneth D Bloch; Marc J Semigran
Journal:  Circulation       Date:  2007-09-04       Impact factor: 29.690

9.  Intravenous sildenafil and inhaled nitric oxide: a randomised trial in infants after cardiac surgery.

Authors:  Christian Stocker; Daniel J Penny; Christian P Brizard; Andrew D Cochrane; Rodrigo Soto; Lara S Shekerdemian
Journal:  Intensive Care Med       Date:  2003-10-07       Impact factor: 17.440

10.  Sildenafil effects on exercise, neurohormonal activation, and erectile dysfunction in congestive heart failure: a double-blind, placebo-controlled, randomized study followed by a prospective treatment for erectile dysfunction.

Authors:  Edimar Alcides Bocchi; Guilherme Guimarães; Amilcar Mocelin; Fernando Bacal; Giovanni Bellotti; José Franchini Ramires
Journal:  Circulation       Date:  2002-08-27       Impact factor: 29.690

View more
  13 in total

Review 1.  Heart failure in single right ventricle congenital heart disease: physiological and molecular considerations.

Authors:  Anastacia M Garcia; Jonathan-Thomas Beatty; Stephanie J Nakano
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-02-28       Impact factor: 4.733

2.  Evaluation of the Tolerability of Intermittent Intravenous Sildenafil in Pediatric Patients With Pulmonary Hypertension.

Authors:  Robyn A Fender; Ty E Hasselman; Yanzhi Wang; Aaron A Harthan
Journal:  J Pediatr Pharmacol Ther       Date:  2016 Sep-Oct

Review 3.  Design and rationale of the Fontan Udenafil Exercise Longitudinal (FUEL) trial.

Authors:  David J Goldberg; Victor Zak; Bryan H Goldstein; Brian W McCrindle; Shaji C Menon; Kurt R Schumacher; R Mark Payne; Jonathan Rhodes; Kimberly E McHugh; Daniel J Penny; Felicia Trachtenberg; Michelle S Hamstra; Marc E Richmond; Peter C Frommelt; Matthew D Files; James L Yeager; Victoria L Pemberton; Mario P Stylianou; Gail D Pearson; Stephen M Paridon
Journal:  Am Heart J       Date:  2018-04-03       Impact factor: 4.749

4.  Results of the FUEL Trial.

Authors:  David J Goldberg; Victor Zak; Bryan H Goldstein; Kurt R Schumacher; Jonathan Rhodes; Daniel J Penny; Christopher J Petit; Salil Ginde; Shaji C Menon; Seong-Ho Kim; Gi Beom Kim; Todd T Nowlen; Michael V DiMaria; Benjamin P Frischhertz; Jonathan B Wagner; Kimberly E McHugh; Brian W McCrindle; Amanda J Shillingford; Arash A Sabati; Anji T Yetman; Anitha S John; Marc E Richmond; Matthew D Files; R Mark Payne; Andrew S Mackie; Christopher K Davis; Shabana Shahanavaz; Kevin D Hill; Ruchira Garg; Jeffrey P Jacobs; Michelle S Hamstra; Stacy Woyciechowski; Kathleen A Rathge; Michael G McBride; Peter C Frommelt; Mark W Russell; Elaine M Urbina; James L Yeager; Victoria L Pemberton; Mario P Stylianou; Gail D Pearson; Stephen M Paridon
Journal:  Circulation       Date:  2019-11-17       Impact factor: 29.690

5.  Effect of Tadalafil on Myocardial and Endothelial Function and Exercise Performance After Modified Fontan Operation.

Authors:  Mohammad-Reza Sabri; Ali Zolfi-Gol; Alireza Ahmadi; Shaghayegh Haghjooy-Javanmard
Journal:  Pediatr Cardiol       Date:  2015-07-28       Impact factor: 1.655

6.  Routine Sildenafil Does Not Improve Clinical Outcomes After Fontan Operation.

Authors:  J Leslie Gaddis Collins; Mark A Law; Santiago Borasino; W Clinton Erwin; David C Cleveland; Jeffrey A Alten
Journal:  Pediatr Cardiol       Date:  2017-09-07       Impact factor: 1.655

7.  Effect of Inhaled Nitric Oxide on Blood Flow Dynamics in Patients After the Fontan Procedure Using Cardiovascular Magnetic Resonance Flow Measurements.

Authors:  Heiner Latus; Bettina Gerstner; Gunter Kerst; Axel Moysich; Kerstin Gummel; Christian Apitz; Juergen Bauer; Dietmar Schranz
Journal:  Pediatr Cardiol       Date:  2015-11-07       Impact factor: 1.655

8.  Results of a phase I/II multi-center investigation of udenafil in adolescents after fontan palliation.

Authors:  David J Goldberg; Victor Zak; Bryan H Goldstein; Shan Chen; Michelle S Hamstra; Elizabeth A Radojewski; Eileen Maunsell; Seema Mital; Shaji C Menon; Kurt R Schumacher; R Mark Payne; Mario Stylianou; Jonathan R Kaltman; Tina M deVries; James L Yeager; Stephen M Paridon
Journal:  Am Heart J       Date:  2017-03-06       Impact factor: 4.749

9.  The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases.

Authors:  Ghazwan Butrous
Journal:  Glob Cardiol Sci Pract       Date:  2014-10-16

10.  Pediatric Pulmonary Hypertension: Definitions, Mechanisms, Diagnosis, and Treatment.

Authors:  Devashis Mukherjee; Girija G Konduri
Journal:  Compr Physiol       Date:  2021-06-30       Impact factor: 8.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.